Troponin in hematologic oncology

References

• Adams J E, III, Abendschein D R, Jaffe A S. Biochemical markers of myocardial injury: is MB creatine kinase the choice for the 1990s?. Circulation 1993; 88: 750–763
   PubMed Web of Science ®Google Scholar
• Bodor G S, Porterfield D, Voss E M, Smith S, Apple F S. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995; 41: 1710–1715
   PubMed Web of Science ®Google Scholar
• Apple F S, Quist H E, Doyle P J, Otto A P, Murakami M M. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003; 49: 1331–1336
   PubMed Web of Science ®Google Scholar
• Katus H A, Remppis A, Scheffold T, Diederich K W, Kuebler W. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol 1991; 67: 1360–1367
   PubMed Web of Science ®Google Scholar
• Adamcova M, Simunek T, Kaiserova H, Popelova O, Sterba M, Potacova A, et al. In vitro and in vivo examination of cardiac troponins as biochemical markers of drug-induced cardiotoxicity. Toxicology 2007; 237: 218–228
   PubMed Web of Science ®Google Scholar
• Urbanova D, Urban L, Carter A, Maasova D, Mladosievicova B. Cardiac troponins: biochemical markers of cardiac toxicity after cytostatic therapy. Neoplasma 2006; 53: 183–190
   PubMed Web of Science ®Google Scholar
• Adamcova M, Gersl V, Hrdina R, Melka M, Mazurova Y, Vavrova J, et al. Cardiac troponin T as a marker of myocardial damage caused by antineoplastic drugs in rabbits. J Cancer Res Clin Oncol 1999; 125: 268–274
   PubMed Web of Science ®Google Scholar
• Herman E H, Zhang J, Lipshultz S E, Rifai N, Chadwick D, Takeda K, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237–2243
   PubMed Web of Science ®Google Scholar
• Bertinchant J P, Polge A, Juan J M, Oliva-Lauraire M C, Giuliani I, Marty-Double C, et al. Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 2003; 329: 39–51
   PubMed Web of Science ®Google Scholar
• Simunek T, Klimtova I, Adamcova M, Gersl V, Hrdina R, Sterba M, et al. Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy. Cancer Chemother Pharmacol 2003; 52: 431–434
   PubMed Web of Science ®Google Scholar
• Koh E, Nakamura T, Takahashi H. Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 2004; 68: 163–167
   PubMed Web of Science ®Google Scholar
• Fauci A S, Harley J B, Roberts W C, Ferrans V J, Gralnick H R, Bjornson B H. NIH conference. The idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97: 78–92
   PubMed Web of Science ®Google Scholar
• Sato Y, Taniguchi R, Yamada T, Nagai K, Makiyama T, Okada H, et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000; 39: 350
   PubMed Web of Science ®Google Scholar
• Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102: 3456–3457
   PubMed Web of Science ®Google Scholar
• McCarthy L J, Danielson C F, Skipworth E M, Peters S L, Miraglia C C, Antony A C. Myocardial infarction/injury is relatively common at presentation of acute thrombotic thrombocytopenic purpura: the Indiana University experience. Ther Apher 2002; 6: 2–4
   PubMedGoogle Scholar
• Askiti V, Hendrickson K, Fish A J, Braunlin E, Sinaiko A R. Troponin I levels in a hemolytic uremic syndrome patient with severe cardiac failure. Pediatr Nephrol 2004; 19: 345–348
   PubMed Web of Science ®Google Scholar
• Thayu M, Chandler W L, Jelacic S, Gordon C A, Rosenthal G L, Tarr P I. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol 2003; 18: 286–289
   PubMed Web of Science ®Google Scholar
• Patschan D, Witzke O, Duhrsen U, Erbel R, Philipp T, Herget-Rosenthal S. Acute myocardial infarction in thrombotic microangiopathies: clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 2006; 21: 1549–1554
   PubMed Web of Science ®Google Scholar
• Lim E, Li Choy L, Flaks L, Mussa S, Van Tornout F, Van Leuven M, et al. Detected troponin elevation is associated with high early mortality after lung resection for cancer. J Cardiothorac Surg 2006; 1: 37
   PubMed Web of Science ®Google Scholar
• Sokol G H, Knudsen J K, Murto A, Cantilena L R. Utilization of troponin I as an index of chemo/radio therapy-induced cardiac toxicity [abstract]. Clin Pharmacol Ther 2001; 69: P47
   Web of Science ®Google Scholar
• Fink F M, Genser N, Fink C, Falk M, Mair J, Maurer-Dengg K, et al. Cardiac troponin T and creatine kinase MB mass concentrations in children receiving anthracycline chemotherapy. Med Pediatr Oncol 1995; 25: 185–189
   PubMedGoogle Scholar
• Lipshultz S E, Rifai N, Sallan S E, Lipsitz S R, Dalton V, Sacks D B, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641–2648
   PubMed Web of Science ®Google Scholar
• Mathew P, Suarez W, Kip K, Bayar E, Jasty R, Matloub Y, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in pediatric patients receiving anthracycline-based therapy? A pilot study. Cancer Invest 2001; 19: 352–359
   PubMed Web of Science ®Google Scholar
• Kremer L C, Bastiaansen B A, Offringa M, Lam J, van Straalen J P, de Winter R J, et al. Troponin T in the first 24 hours after the administration of chemotherapy and the detection of myocardial damage in children. Eur J Cancer 2002; 38: 686–689
   PubMed Web of Science ®Google Scholar
• Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Buyukpamukcu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42: 220–224
   PubMed Web of Science ®Google Scholar
• Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005; 26: 1197–1202
   PubMed Web of Science ®Google Scholar
• Koseoglu V, Berberoglu S, Karademir S, Kismet E, Yurttutan N, Demirkaya E, et al. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?. Turk J Pediatr 2005; 47: 17–22
   PubMed Web of Science ®Google Scholar
• Erkus B, Demirtas S, Yarpuzlu A A, Can M, Genc Y, Karaca L. Early prediction of anthracycline induced cardiotoxicity. Acta Paediatr 2007; 96: 506–509
   PubMed Web of Science ®Google Scholar
• Clark S J, Pippon M, Hemsworth S, Newland P, Pizer B. Cardiac troponin T following anthracycline chemotherapy in children and adolescents. J Chemother 2007; 19: 332–334
   PubMed Web of Science ®Google Scholar
• Hughes-Davies L, Sacks D, Rescigno J, Howard S, Harris J. Serum cardiac troponin T levels during treatment of early-stage breast cancer. J Clin Oncol 1995; 13: 2582–2584
   PubMed Web of Science ®Google Scholar
• Benvenuto G M, La Vecchia L, Morandi P, Ruffini P, Mezzena G. Assessment of cardiotoxicity of high dose cyclophosphamide with electrocardiographic, echocardiographic, and troponin I monitoring in patients with breast tumors. Ital Heart J Suppl 2000; 1: 1457–1463
   PubMedGoogle Scholar
• Morandi P, Ruffini P A, Benvenuto G M, La Vecchia L, Mezzena G, Raimondi R. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m2) cyclophosphamide. Bone Marrow Transplant 2001; 28: 277–282
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri M T, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13: 710–715
   PubMed Web of Science ®Google Scholar
• Nistico C, Bria E, Cuppone F, Carpino A, Ferretti G, Vitelli G, et al. Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients. Anticancer Drugs 2007; 18: 227–232
   PubMed Web of Science ®Google Scholar
• Hogg D, Croal B, Culligan D, Struthers A, Cowie M. Brain natriuretic peptide and cardiac troponin I as markers of doxorubicin cardiotoxicity. Blood 2001; 96: 239b
   Web of Science ®Google Scholar
• Horacek J M, Pudil R, Tichy M, Jebavy L, Strasova A, Praus R, et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430–434
   PubMed Web of Science ®Google Scholar
• Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. Monitoring of cardiac function on the basis of serum troponin I levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med 2005; 145: 212–220
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri M T, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517–522
   PubMed Web of Science ®Google Scholar
• Auner H W, Tinchon C, Brezinschek R I, Eibl M, Sormann S, Maizen C, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1–6
   PubMed Web of Science ®Google Scholar
• Sandri M T, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003; 49: 248–252
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri M T, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749–2754
   PubMed Web of Science ®Google Scholar
• Missov E, Calzolari C, Davy J M, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997; 8: 537–541
   PubMed Web of Science ®Google Scholar
• Auner H W, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218–222
   PubMed Web of Science ®Google Scholar
• Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol 2005; 16: 798–804
   PubMed Web of Science ®Google Scholar
• Dolci A, Dominici R, Cardinale D, Sandri M T, Panteghini M. Biochemical markers for predicting chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. G Ital Cardiol (Rome) 2006; 7: 604–611
   PubMedGoogle Scholar
• Polena S, Shikara M, Naik S, Chouhdry F, Sharma M, Gintautas J, et al. Troponin I as a marker of doxorubicin induced cardiotoxicity. Proc West Pharmacol Soc 2005; 48: 142–144
   PubMedGoogle Scholar
• Ferretti G, Mandala M, Bria E, Papaldo P, Carlini P, Fabi A, et al. Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?. Ann Oncol 2005; 16: 1403–1404
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Sandri M T, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474–2481
   PubMed Web of Science ®Google Scholar
• Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari A L, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2006; 47: 2174–2180
   PubMed Web of Science ®Google Scholar
• Assiri A MA, Abdel-Wahab A FI. Carnosine protects against doxorubicin-induced cardiotoxicity. Saudi Pharm J 2003; 11: 23–31
   Google Scholar
• Cvetkovic R S, Scott L J. Dexrazoxane: A review of its use for cardioprotection during anthracycline chemotherapy. Drugs 2005; 65: 1005–1024
   PubMed Web of Science ®Google Scholar
• Herman E H, Zhang J, Rifai N, Lipshultz S E, Hasinoff B B, Chadwick D P, et al. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 2001; 48: 297–304
   PubMed Web of Science ®Google Scholar
• Lipshultz S E. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol 2006; 33(3 Suppl 8)S8–S14
   PubMed Web of Science ®Google Scholar
• Lipshultz S E, Rifai N, Dalton V M, Levy D E, Silverman L B, Lipsitz S R, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145–153
   PubMed Web of Science ®Google Scholar
• Oztop I, Gencer M, Okan T, Yaren A, Altekin E, Turker S, et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 2004; 34: 262–268
   PubMed Web of Science ®Google Scholar
• Willging S, Keller F, Steinbach G. Specificity of cardiac troponins I and T in renal disease. Clin Chem Lab Med 1998; 36: 87–92
   PubMed Web of Science ®Google Scholar
• Gibson T N, Hanchard B. False positive troponin I in a case of metastatic small cell bronchogenic carcinoma complicated by pulmonary thromboembolism. West Indian Med J 2001; 50: 171–172
   PubMed Web of Science ®Google Scholar
• Hamilton J S, Sharpe P C. Two cases of inflammatory muscle disease presenting with raised serum concentrations of troponin T. J Clin Pathol 2005; 58: 1323–1324
   PubMed Web of Science ®Google Scholar
• Isotalo P A, Greenway D C, Donnelly J G. Metastatic alveolar rhabdomyosarcoma with increased serum creatine kinase MB and cardiac troponin T and normal cardiac troponin I. Clin Chem 1999; 45: 1576–1578, [erratum in 2000; 46:582]
   PubMed Web of Science ®Google Scholar
• Agewall S. Increases of creatine kinase MB and cardiac troponin T in serum of a patient with uterine leiomyosarcoma. Clin Chem 2000; 46: 2016–2017
   PubMed Web of Science ®Google Scholar
• Miller W L, Wright R S, McGregor C G, Dispenzieri A, McConnell J P, Burritt M F, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol 2001; 88: 813–815
   PubMed Web of Science ®Google Scholar
• Miller W L, Dispenzieri A, Jaffe A S, Chandrasekaran K, McConnell J P, Burritt M F. Elevated serum troponin levels predict short-term mortality in patients with systemic amyloidosis [abstract]. J Am Coll Cardiol 2003; 41: 197A
   PubMed Web of Science ®Google Scholar
• Cantwell R V, Aviles R J, Bjornsson J, Wright R S, Freeman W K, Oh J K, et al. Cardiac amyloidosis presenting with elevations of cardiac troponin I and angina pectoris. Clin Cardiol 2002; 25: 33–37
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle R A, Gertz M A, Therneau T M, Miller W L, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787–1789
   PubMed Web of Science ®Google Scholar
• Zabernigg A, Schranzhofer R, Kreczy A, Gattringer K. Continuously elevated cardiac troponin I in two patients with multiple myeloma and fatal cardiac amyloidosis. Ann Oncol 2003; 14: 1791
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M A, Kyle R A, Lacy M Q, Burritt M F, Therneau T M, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751–3757
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Gertz M A, Kyle R A, Lacy M Q, Burritt M F, Therneau T M, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–1887
   PubMed Web of Science ®Google Scholar
• Bahlis N J, Lazarus H M. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?. Bone Marrow Transplant 2006; 38: 7–15
   PubMed Web of Science ®Google Scholar
• Kristen A V, Meyer F J, Perz J B, Schonland S O, Hundemer M, Hegenbart U, et al. Risk stratification in cardiac amyloidosis: novel approaches. Transplantation 2005; 80(1 Suppl)S151–S155
   PubMed Web of Science ®Google Scholar
• Kato T, Sato Y, Nagao K, Horie T, Kataoka K, Miyamoto T, et al. Serum cardiac troponin T in cardiac amyloidosis: serial observations in five patients. Tohoku J Exp Med 2006; 208: 163–167
   PubMed Web of Science ®Google Scholar
• Wallace K B, Hausner E, Herman E, Holt G D, MacGregor J T, Metz A L, et al. Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 2004; 32: 106–121
   PubMed Web of Science ®Google Scholar